Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related 25 mosquito-borne flaviviruses. Japanese encephalitis (JE) vaccine SA14-14-2 has been in 26 the Chinese national Expanded Program on Immunization since 2007. The recent 27 recognition of severe disease syndromes associated with ZIKV, and the identification of 28 ZIKV from mosquitoes in China, prompts an urgent need to investigate the potential 29 interaction between the two. In this study, we showed that SA14-14-2 is protective against 30 ZIKV infection in mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive 31 immune responses to ZIKV; however, it was cellular immunity that predominantly 32 mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not 33 result in significant cross-protection, but did mediate antibody dependent enhancement in 34 vitro, though this did not have an adverse impact on survival. This study suggests that 35 SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response.
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Three weeks after the final immunization, sera were collected from C57BL/6 mice. Serially 168 ten-fold-diluted sera were incubated with JEV or ZIKV at a multiplicity of infection of 2 for 169 one hour at 37 °C before adding to THP-1 cells. Samples were incubated for two hours at 170 37 °C and gently shaken every 15 min. Cells were centrifuged and washed three times, 171 followed by resuspension in fresh RPMI-1640 medium and incubated for three days at 172 37 °C. Supernatants were collected and viral titer measured by plaque assay on Vero 173 cells as described (18) . Fold enhancement was calculated by comparison to viral titers in 174 the absence of immune sera.
175
Enzyme-linked immunospot (ELISPOT) assays 176 Three weeks after the final immunization, the cytokines IL-2, IL-4, and IFN-γ secreted by 177 splenocytes of C57BL/6 mice were determined using ELISPOT kits (BD, USA) according 178 to the manufacturer's instructions. In brief, mouse splenocytes were plated at 3 × 10 5 / well 179 into 96-well filtration plates (Millipore, USA) pre-coated with capture antibodies and 180 stimulated with 5 µg / well purified JEV or ZIKV particles for 60 h at 37 °C. After incubation 181 with biotinylated detection antibody, the spots were visualized by adding 182 streptavidin-horseradish peroxidase and 3-amino-9-ethylcarbazole substrate, counted 183 automatically with an ELISPOT reader (CTL, USA) and analyzed by ImmunoSpot 184 software (version 5.1). Splenocytes cocultured with concanavalin A served as a positive 185 control, and those cultured with RPMI 1640 medium served as a negative control.
186
Adoptive transfer and cross-reactive protection of splenocytes from 187 SA14-14-2-immunized C57BL/6 mice in Ifnar -/mice 188 Three weeks after the final vaccination, splenocytes were isolated from the immunized 189 C57BL/6 mice using lymphocyte separation percoll (Solarbio, China). A total of 3 × 10 6 190 lymphocytes was transfused retro-orbitally (r.o.) to female adult Ifnar -/mice. After 24 h, 191 the mice were challenged i.c. with a lethal dose of either JEV (Beijing-1 strain, 10 4 PFU) or 192 ZIKV (SMGC-1 strain, 10 4 PFU). Body weight and mortality were monitored daily for 14 193 consecutive days. Mice exhibiting more than 25% loss in body weight were humanely 194 euthanized for ethical reasons.
195

Statistical analysis
196
Statistical analyses were performed using SPSS statistics version 17.0 (SPSS Inc., USA).
197
Geometric mean titers (GMTs) were calculated after log transformation of reciprocal titers. 
219
1B and 1C). Vaccinated mice maintained a normal body weight whereas control mice 220 showed significant weight loss (approximately 16%) and most of them died within 9 days
221
(1/6 survival). These data suggest that vaccination with SA14-14-2 in Ifnar -/mice induced 222 in vivo cross-reactive immunity, conferring effective cross-protection against lethal ZIKV 223 infection.
224
Cross-protection against ZIKV infection is not mediated by SA14-14-2-immune sera
225
There is a clearly established role for nAb in protection from flaviviruses. Therefore, in 226 order to evaluate cross-reactive neutralization of ZIKV induced by SA14-14-2 vaccination, 227 three weeks after the final immunization, sera were collected from C57BL/6 mice and the 228 nAb titers were assayed by PRNT ( Fig. 2A ). As expected, mice administered three doses 229 of JEV SA14-14-2 developed a high level of JEV-specific nAb, with a GMT of 1:494 ( Fig. 
230
2B). In contrast, JEV SA14-14-2 antisera from the immunized mice failed to neutralize 231 ZIKV, and the PRNT 50 titer of antisera was comparable to that of controls. This result 232 suggests that nAb elicited by JEV SA14-14-2 yielded no neutralizing activity against ZIKV.
233
To further test whether JEV SA14-14-2 antisera would cross-protect mice against ZIKV 234 challenge in vitro, for example by a mechanism distinct from neutralization, immune sera 10 The effect is common among flaviviruses (25). Therefore, in order to determine whether 279 SA14-14-2-immune sera could promote ADE of ZIKV infectivity in vitro, we exposed 280 FcγRI/II-bearing cell line THP-1 to ZIKV in the presence or absence of 281 SA14-14-2-immune sera. We observed dose dependent enhancement of infection from a 282 dilution of 1:100, which peaked at 1:10,000 dilution, with ZIKV infection enhancement up 283 to 79.7-fold ( Fig. 3D) . In contrast, sera from control mice did not significantly enhance the 284 infectivity of ZIKV, although modest enhancement at a dilution of 1:10,000, likely to due to 285 non-specific effect. Meanwhile, when THP-1 cells were infected in the presence of the 286 SA14-14-2-immune sera, we found that they also yielded a 17.0-fold greater infection of 287 JEV at a dilution of 1:10,000 than those in the absence of sera (Fig. 3D ). This homotypical 288 enhancement is most likely the result of sub-or non-neutralizing titer of serum dilution. As 289 expected, control sera did not obviously enhance JEV infection. In summary, the result 290 demonstrates that cross-reactive anti-JEV antibodies can promote ADE of ZIKV, at least 291 in vitro.
292
Multiple cross-reactive cytokine responses to ZIKV
293
Having provided indirect evidence that both Th1 and Th2 responses were made following 294 SA14-14-2 vaccination, and that these responses could cross-react with ZIKV, albeit not 295 with protective nAb, we sought to determine the nature of the T helper response after 296 SA14-14-2-vaccination. Three weeks after the third and final immunization, splenocytes 297 were collected from the C57BL/6 mice. The levels of splenocyte-derived IL-2, IL-4, and 298 IFN-γ were determined by ELISPOT assay (Fig. 4) . Notably, when pulsed with ZIKV 299 antigen, splenocytes from SA-14-14-2-immunized mice responded by making all three 300 cytokines, although the levels were lower when compared with responses of 301 SA-14-14-2-immune splenocytes upon stimulation with JEV antigen. IL-2 and IFN-γ are 302 predominant markers of the Th1 response, IL-4 expression is defined as a marker of the 303 Th2 response. The results indicated that either the Th1-or the Th2-type cross-reactive 304 immune responses against ZIKV was evoked by administration of the JEV SA-14-14-2 305 vaccine.
306
Cell-mediated immunity as a potential mechanism of cross-protection against ZIKV
307
Although multiple cytokines can be produced under ZIKV antigen stimulation, it was 308 unclear whether cellular immunity was indispensible or essential for the in vivo 309 cross-reactive protection. Therefore, adoptive transfer of immune splenocytes from 310 SA14-14-2-immunized C57BL/6 mice into naïve Ifnar -/recipient mice was performed 311 three weeks after the final immunization, followed by viral challenge with a lethal dose of 312 JEV or ZIKV (Fig. 5A) . After JEV challenge, mice receiving splenocytes derived from 313 control group showed marked and up to 26.7% body weight loss, all mice died (0/6) within 314 nine days, whereas 100% (6/6) of mice receiving SA14-14-2-immune splenic lymphocytes 315 11 survived without obvious weight change ( Fig. 5B and C ), suggesting that a protective 316 prototype of splenocytes activated by SA14-14-2 was successfully established.
317
Meanwhile, while naïve Ifnar -/recipient mice in control group showed high susceptibility to 318 ZIKV infection with weight loss of 17.0% and only 16.7% (1/6) survival rate, virtually 319 83.3% (5/6) of mice infused with SA14-14-2-immune lymphocytes survived the lethal ZIKV 320 challenge with only a weight loss of 5.8% (Fig. 5B and C) . Taken together with our nAb 321 data, this result demonstrated that a cell-mediated cross-reactive response induced by 322 SA14-14-2-immunization was protective against subsequent ZIKV infection.
323
Discussion 324
It is becoming increasingly apparent that the pre-existing immunity triggered by primary 
338
Previously, we found that live attenuated JE vaccine SA-14-14-2 conferred 339 cross-reactive nAbs which contributed to the cross-protection against DENV challenge 340 (16). In contrast to this result, in this study, mice immunized with SA14-14-2 showed a 341 cross-reactive IgG antibody response to ZIKV without the presence of neutralizing activity 342 ( Figs. 2B and 3B ). Although the ADE in SA14-14-2-immune sera was detected in vitro ( Fig.   343 3D), we found no evidence that this resulted in a harmful effect; indeed, in subsequent 344 ZIKV challenge, SA14-14-2 vaccination slightly lengthened the median survival (Fig. 2D) .
345
This is an important result, suggesting that cross-reactive antibodies from SA14-14-2 346 vaccination are not pathogenic in vivo, because many people in Asia have received 347 inactivated JE vaccine which will generate anti-JEV nAb but may not contain many of the 348 cross-reactive T cell epitopes, which lie in the NS proteins (28). Here, we use neonatal 349 C57BL/6 mice instead of neonatal Ifnar -/mice because the former is susceptible to ZIKV 350 and can mimic the signs (18). Although SA14-14-2 vaccine triggered both Th1 and Th2 351 responses (Figs. 4B and 3C) , adoptive splenocyte transfer was superior to serum transfer 12 in protection against ZIKV infection, implying a strong correlation between 353 SA14-14-2-induced cellular immunity and the ZIKV-cross-protective capacity. However, 354 the limitation in this study is that we did not elucidate the functional components which are 355 cross-protective by further sorting of splenocytes for adoptive transfer, such as purified T 356 cells or their subpopulations (CD8 + or CD4 + alone), or cross-reactive memory B cells.
357
Furthermore, we did not determine whether the cross-reactive nAb response was present 358 in recipient mice transferred with SA14-14-2-immune splenocytes, although this is unlikely 359 to change our primary conclusions.
360
Traditionally, based on cross-neutralizing activity, flaviviruses have been subdivided 361 into distinct serocomplexes. Cross neutralization between different serocomplexes is 362 usually not observed (4). The flavivirus E protein is the principal antigen against which the 363 nAb response is directed. The extent of cross-neutralization correlates with the amino acid 364 sequence identity of E protein: when the sequence identity in E protein is less than 40%, 365 cross neutralization is lost (29). JEV and ZIKV belong to distinct serocomplexes, although 366 the homology of the E protein amino acid sequence between the JEV SA14-14-2 strain 367 and the ZIKV SMGC-1 strain was 53.4%, the distinct epitopes in E proteins of JEV and 368 ZIKV within different flaviviruses that dominate antibody responses are presumably 369 responsible for the unavailable cross-neutralization (30). For the sequence homology of 370 the E protein, ZIKV is more closely related to the DENV than to the JEV serocomplex (4).
371
However, most B cell epitopes are conformational (31), and therefore, sequence 
375
Nevertheless, despite this structural similarity, this did not account for protection in the 376 model we describe here.
377
In contrast, NS proteins among flaviviruses are more conserved with up to 68.0% 378 identity than structural proteins. Weiskopf et al. indicated that, following heterologous 379 DENV infection, memory CD8 + T cells expanded that recognized conserved NS proteins 380 (33). In fact, NS3 and NS5 represent the main targets of the CD8 + T cell response to 381 flaviviruses (34, 35) . One study reported more cross-reactive T cell responses to full 382 length NS3 helicase, because of higher sequence homology, than that to the protease 383 region alone (36). Also, a homologous analysis based on the NS5 protein would place 384 ZIKV closer to the JEV serocomplex than to DENVs (37). In our study, we hypothesise 385 that it is the cross-reactive response to shared T cell epitopes in the NS proteins that 386 contributes to protection mediated by adoptive transfer of immune splenocytes.
387
In a mouse model, CD8 + T cells can mediate protection against ZIKV (35).
388
DENV-specific cross-reactive CD8 + T cells can also protect (38), and similar responses 389 are detected in humans, where cross-reactive CD8 + T cells specific for DENV display 13 anti-ZIKV effector potential toward ZIKV, mediating direct cytolysis (39). JEV / ZIKV share 391 63.9% and 68.0% homology in NS3 and NS5, respectively. Our findings are consistent 392 with a cross-reactive CD8 + T cell mediating protection, but characterization of the key 393 components responsible for cross-protection in splenic lymphocytes, and identification of 394 JEV/ZIKV cross-reactive epitopes, warrant further investigation.
395
Since 2007, China has included a two-shot schedule of the JEV SA14-14-2 vaccine into 396 the national Expanded Program on Immunization. Children under the age of 13 and even 397 older children in some provinces of China have pre-existing JEV immunity. It should be 398 noted that, according to the eatablished schedule, children are received the SA14-14-2 399 vaccine at eight months and two years of age, but three immunizations in mice were 400 performed in this study, as previously (16) 
409
In conclusion, the results of our study demonstrated that JEV SA14-14-2 elicited 410 effective cross-protection against ZIKV in mice. Our results indicate the potential for the 411 widespread use of the vaccine, especially in those co-circulating countries. Moreover, this 412 study will provide important information in terms of ZIKV prevention or precaution.
413
Furthermore, it is worthwhile to identify common epitopes for the future development of a 414 novel bivalent vaccine based on T cell against both JEV and ZIKV. 415 416
